Galectin Therapeutics (GALT) Stock Price, News & Analysis

Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Key Stats

• Today's Range: $3.97 to $4.35
• 50-Day Range: $2.09 to $4.25
• 52-Week Range: $0.73 to $4.41
• Volume: 275,225 shs
• Average Volume: 247,439 shs
• Market Capitalization: $272.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

Galectin Therapeutics Stock Analysis - MarketRank™

Galectin Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 596th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Galectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Galectin Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.73) to ($0.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Galectin Therapeutics is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Galectin Therapeutics is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.76% of the float of Galectin Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Galectin Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Galectin Therapeutics has recently increased by 0.13%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galectin Therapeutics does not currently pay a dividend.

Dividend Growth

Galectin Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.76% of the float of Galectin Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Galectin Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Galectin Therapeutics has recently increased by 0.13%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.31

News Sentiment

Galectin Therapeutics has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Galectin Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 7 people have searched for GALT on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

MarketBeat Follows

6 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Galectin Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,920.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

50.10% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.68% of the stock of Galectin Therapeutics is held by institutions.

GALT Stock Analysis - Frequently Asked Questions

How have GALT shares performed this year?

Galectin Therapeutics' stock was trading at $1.29 at the start of the year. Since then, GALT shares have increased by 229.5% and is now trading at $4.25.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) announced its quarterly earnings results on Thursday, August, 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.04.

Who are Galectin Therapeutics' major shareholders?

Top institutional shareholders of Galectin Therapeutics include Jane Street Group LLC (1.18%), Geode Capital Management LLC (1.05%), Wealthspire Advisors LLC (0.76%) and Affinity Asset Advisors LLC. Insiders that own company stock include James C Czirr, Joel Lewis, Kary Eldred, Richard A Jr Zordani, Kevin D Freeman, Khurram Jamil, Harold H Shlevin and Jack W Callicutt.
View institutional ownership trends.

How do I buy shares of Galectin Therapeutics?

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GALT
• CIK: 1133416
• Web: www.galectintherapeutics.com
• Phone: (678) 620-3186
• Fax: 770-864-1327
• Employees: 9
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Galectin Therapeutics: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +41.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.05 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -225.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.43
• Quick Ratio: 1.43

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.86) per share
• Price / Book: -2.28

Miscellaneous

• Outstanding Shares: 64,060,000
• Free Float: 31,966,000
• Market Cap: $272.26 million
• Optionable: Optionable
• Beta: 0.82